WoS
🏆 JCR Q2 · JIF 3,1
YÖKSİS Eşleşti
2025 Editorial material 1. Yazar
Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?
FUTURE ONCOLOGY
·
Cilt 21, s. 3589-3592
·
ISSN 1479-6694
Prof. Dr. RAFİYE ÇİFTÇİLER
· 2 yazar
WoS
🏆 JCR Q4 · JIF 0,4
YÖKSİS Eşleşti
2019 Article 1. Yazar
Fibrosis Development, Leukemic Transformation and Secondary Malignancies Complicating the Clinical Course of Essential Thrombocythemia
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
·
Cilt 29, s. 14-21
·
ISSN 1306-133X
Prof. Dr. RAFİYE ÇİFTÇİLER
· 5 yazar